Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 30 entries
Sorted by: Best Match Show Resources per page
Adhesion Molecule L1 Agonist Mimetics Protect Against the Pesticide Paraquat-Induced Locomotor Deficits and Biochemical Alterations in Zebrafish.

Frontiers in neuroscience

Joseph TP, Jagadeesan N, Sai LY, Lin SL, Sahu S, Schachner M.
PMID: 32547358
Front Neurosci. 2020 May 28;14:458. doi: 10.3389/fnins.2020.00458. eCollection 2020.

Besides several endogenous elements, exogenous factors, including exposure to pesticides, have been recognized as putative factors contributing to the onset and development of neurodegenerative diseases, including Parkinson's disease (PD). Considering the availability, success rate, and limitations associated with the...

Cite
Joseph TP, Jagadeesan N, Sai LY, et al. Adhesion Molecule L1 Agonist Mimetics Protect Against the Pesticide Paraquat-Induced Locomotor Deficits and Biochemical Alterations in Zebrafish. Front Neurosci. 2020;14:458doi: 10.3389/fnins.2020.00458.
Joseph, T. P., Jagadeesan, N., Sai, L. Y., Lin, S. L., Sahu, S., & Schachner, M. (2020). Adhesion Molecule L1 Agonist Mimetics Protect Against the Pesticide Paraquat-Induced Locomotor Deficits and Biochemical Alterations in Zebrafish. Frontiers in neuroscience, 14458. https://doi.org/10.3389/fnins.2020.00458
Joseph, Thomson Patrick, et al. "Adhesion Molecule L1 Agonist Mimetics Protect Against the Pesticide Paraquat-Induced Locomotor Deficits and Biochemical Alterations in Zebrafish." Frontiers in neuroscience vol. 14 (2020): 458. doi: https://doi.org/10.3389/fnins.2020.00458
Joseph TP, Jagadeesan N, Sai LY, Lin SL, Sahu S, Schachner M. Adhesion Molecule L1 Agonist Mimetics Protect Against the Pesticide Paraquat-Induced Locomotor Deficits and Biochemical Alterations in Zebrafish. Front Neurosci. 2020 May 28;14:458. doi: 10.3389/fnins.2020.00458. eCollection 2020. PMID: 32547358; PMCID: PMC7270331.
Copy Download .nbib Format: NLM
Comprehensive .

ACS pharmacology & translational science

Sacilotto N, Dessanti P, Lufino MMP, Ortega A, Rodríguez-Gimeno A, Salas J, Maes T, Buesa C, Mascaró C, Soliva R.
PMID: 34927013
ACS Pharmacol Transl Sci. 2021 Nov 12;4(6):1818-1834. doi: 10.1021/acsptsci.1c00223. eCollection 2021 Dec 10.

Lysine-specific demethylase 1 (LSD1 or KDM1A) is a chromatin modifying enzyme playing a key role in the cell cycle and cell differentiation and proliferation through the demethylation of histones and nonhistone substrates. In addition to its enzymatic activity, LSD1...

Cite
Sacilotto N, Dessanti P, Lufino MMP, et al. Comprehensive . ACS Pharmacol Transl Sci. 2021;4(6):1818-1834doi: 10.1021/acsptsci.1c00223.
Sacilotto, N., Dessanti, P., Lufino, M. M. P., Ortega, A., Rodríguez-Gimeno, A., Salas, J., Maes, T., Buesa, C., Mascaró, C., & Soliva, R. (2021). Comprehensive . ACS pharmacology & translational science, 4(6), 1818-1834. https://doi.org/10.1021/acsptsci.1c00223
Sacilotto, Natalia, et al. "Comprehensive ." ACS pharmacology & translational science vol. 4,6 (2021): 1818-1834. doi: https://doi.org/10.1021/acsptsci.1c00223
Sacilotto N, Dessanti P, Lufino MMP, Ortega A, Rodríguez-Gimeno A, Salas J, Maes T, Buesa C, Mascaró C, Soliva R. Comprehensive . ACS Pharmacol Transl Sci. 2021 Nov 12;4(6):1818-1834. doi: 10.1021/acsptsci.1c00223. eCollection 2021 Dec 10. PMID: 34927013; PMCID: PMC8669716.
Copy Download .nbib Format: NLM
Effect of Monoamine Oxidase Inhibition, Thiopental Anesthesia, and Electroconvulsive Shock (ECS).

Convulsive therapy

Rynearson RR, Raebel MA, Engvall WR, Spiekerman MA, Hillis A, Gross D.
PMID: 11941057
Convuls Ther. 1990;6(2):153-159.

A series of experiments were conducted to investigate the effect of the monoamine oxidase inhibitor (MAOI), phenelzine, on thiopental anesthesia, electroshock, and blood pressure. After demonstrating that phenelzine (1 mg/kg/day orally) produced the same decrease in pig platelet monoamine...

Cite
Rynearson RR, Raebel MA, Engvall WR, et al. Effect of Monoamine Oxidase Inhibition, Thiopental Anesthesia, and Electroconvulsive Shock (ECS). Convuls Ther. 1990;6(2):153-159
Rynearson, R. R., Raebel, M. A., Engvall, W. R., Spiekerman, M. A., Hillis, A., & Gross, D. (1990). Effect of Monoamine Oxidase Inhibition, Thiopental Anesthesia, and Electroconvulsive Shock (ECS). Convulsive therapy, 6(2), 153-159.
Rynearson, Robert R., et al. "Effect of Monoamine Oxidase Inhibition, Thiopental Anesthesia, and Electroconvulsive Shock (ECS)." Convulsive therapy vol. 6,2 (1990): 153-159.
Rynearson RR, Raebel MA, Engvall WR, Spiekerman MA, Hillis A, Gross D. Effect of Monoamine Oxidase Inhibition, Thiopental Anesthesia, and Electroconvulsive Shock (ECS). Convuls Ther. 1990;6(2):153-159. PMID: 11941057.
Copy Download .nbib Format: NLM
The treatment of anxiety disorders: a legacy of William Sargant.

European psychiatry : the journal of the Association of European Psychiatrists

Gelder M.
PMID: 19698558
Eur Psychiatry. 1997;12(8):381-6. doi: 10.1016/S0924-9338(97)83562-6.

In 1962 William Sargant and his colleagues described the therapeutic value of phenelzine, a monoamine oxidase inhibitor (MAOI), in chronic anxiety disorders and in the same year Klein and Fink reported the treatment of similar conditions with imipramine, a...

Cite
Gelder M. The treatment of anxiety disorders: a legacy of William Sargant. Eur Psychiatry. 1997;12(8):381-6doi: 10.1016/S0924-9338(97)83562-6.
Gelder, M. (1997). The treatment of anxiety disorders: a legacy of William Sargant. European psychiatry : the journal of the Association of European Psychiatrists, 12(8), 381-6. https://doi.org/10.1016/S0924-9338(97)83562-6
Gelder, M. "The treatment of anxiety disorders: a legacy of William Sargant." European psychiatry : the journal of the Association of European Psychiatrists vol. 12,8 (1997): 381-6. doi: https://doi.org/10.1016/S0924-9338(97)83562-6
Gelder M. The treatment of anxiety disorders: a legacy of William Sargant. Eur Psychiatry. 1997;12(8):381-6. doi: 10.1016/S0924-9338(97)83562-6. PMID: 19698558.
Copy Download .nbib Format: NLM
Acute and chronic antidepressant drug treatments induce opposite effects in the social behaviour of rats.

Journal of psychopharmacology (Oxford, England)

Mitchell PJ, Redfern PH.
PMID: 22291357
J Psychopharmacol. 1992 Jan;6(2):241-57. doi: 10.1177/026988119200600218.

Clinical studies indicate that the behavioural responses/reactions of depressed patients to environmental and social stimulation are modified during remission from depressive illness, and require continuous (at least 3 weeks) drug treatment. In order to determine whether antidepressant drugs modify...

Cite
Mitchell PJ, Redfern PH. Acute and chronic antidepressant drug treatments induce opposite effects in the social behaviour of rats. J Psychopharmacol. 1992;6(2):241-57doi: 10.1177/026988119200600218.
Mitchell, P. J., & Redfern, P. H. (1992). Acute and chronic antidepressant drug treatments induce opposite effects in the social behaviour of rats. Journal of psychopharmacology (Oxford, England), 6(2), 241-57. https://doi.org/10.1177/026988119200600218
Mitchell, P J, and Redfern, P H. "Acute and chronic antidepressant drug treatments induce opposite effects in the social behaviour of rats." Journal of psychopharmacology (Oxford, England) vol. 6,2 (1992): 241-57. doi: https://doi.org/10.1177/026988119200600218
Mitchell PJ, Redfern PH. Acute and chronic antidepressant drug treatments induce opposite effects in the social behaviour of rats. J Psychopharmacol. 1992 Jan;6(2):241-57. doi: 10.1177/026988119200600218. PMID: 22291357.
Copy Download .nbib Format: NLM
Clinical pharmacology of moclobemide, a new reversible monoamine oxidase inhibitor.

Journal of psychopharmacology (Oxford, England)

Warrington SJ, Turner P, Mant TG, Morrison P, Haywood G, Glover V, Goodwi BL, Sandler M, John-Smith PS, McClelland GR.
PMID: 22282124
J Psychopharmacol. 1991 Jan;5(1):82-91. doi: 10.1177/026988119100500112.

The clinical pharmacology of the new reversible monoamine oxidase (MAO) inhibitor, moclobemide, was examined in three separate studies in healthy male volunteers. In a single oral dose study, moclobemide (25-150 mg) was rapidly absorbed from the gastrointestinal tract and...

Cite
Warrington SJ, Turner P, Mant TG, et al. Clinical pharmacology of moclobemide, a new reversible monoamine oxidase inhibitor. J Psychopharmacol. 1991;5(1):82-91doi: 10.1177/026988119100500112.
Warrington, S. J., Turner, P., Mant, T. G., Morrison, P., Haywood, G., Glover, V., Goodwi, B. L., Sandler, M., John-Smith, P. S., & McClelland, G. R. (1991). Clinical pharmacology of moclobemide, a new reversible monoamine oxidase inhibitor. Journal of psychopharmacology (Oxford, England), 5(1), 82-91. https://doi.org/10.1177/026988119100500112
Warrington, S J, et al. "Clinical pharmacology of moclobemide, a new reversible monoamine oxidase inhibitor." Journal of psychopharmacology (Oxford, England) vol. 5,1 (1991): 82-91. doi: https://doi.org/10.1177/026988119100500112
Warrington SJ, Turner P, Mant TG, Morrison P, Haywood G, Glover V, Goodwi BL, Sandler M, John-Smith PS, McClelland GR. Clinical pharmacology of moclobemide, a new reversible monoamine oxidase inhibitor. J Psychopharmacol. 1991 Jan;5(1):82-91. doi: 10.1177/026988119100500112. PMID: 22282124.
Copy Download .nbib Format: NLM
Time to Reconsider Monoamine Oxidase Inhibitors for Obsessive Compulsive Disorder?: A Case Series Using Phenelzine.

Journal of clinical psychopharmacology

Grant JE, Baldwin DS, Chamberlain SR.
PMID: 34108430
J Clin Psychopharmacol. 2021 Jul-Aug 01;41(4):461-464. doi: 10.1097/JCP.0000000000001418.

PURPOSE/BACKGROUND: Despite the availability of a range of efficacious evidence-based treatments for obsessive-compulsive disorder (OCD), not all patients experience sufficient benefit or are able to tolerate them in practice. Monoamine oxidase inhibitors (MAOIs) show efficacy in the treatment of...

Cite
Grant JE, Baldwin DS, Chamberlain SR. Time to Reconsider Monoamine Oxidase Inhibitors for Obsessive Compulsive Disorder?: A Case Series Using Phenelzine. J Clin Psychopharmacol. 2021;41(4):461-464doi: 10.1097/JCP.0000000000001418.
Grant, J. E., Baldwin, D. S., & Chamberlain, S. R. (2021). Time to Reconsider Monoamine Oxidase Inhibitors for Obsessive Compulsive Disorder?: A Case Series Using Phenelzine. Journal of clinical psychopharmacology, 41(4), 461-464. https://doi.org/10.1097/JCP.0000000000001418
Grant, Jon E, et al. "Time to Reconsider Monoamine Oxidase Inhibitors for Obsessive Compulsive Disorder?: A Case Series Using Phenelzine." Journal of clinical psychopharmacology vol. 41,4 (2021): 461-464. doi: https://doi.org/10.1097/JCP.0000000000001418
Grant JE, Baldwin DS, Chamberlain SR. Time to Reconsider Monoamine Oxidase Inhibitors for Obsessive Compulsive Disorder?: A Case Series Using Phenelzine. J Clin Psychopharmacol. 2021 Jul-Aug 01;41(4):461-464. doi: 10.1097/JCP.0000000000001418. PMID: 34108430.
Copy Download .nbib Format: NLM
Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine.

Cellular and molecular neurobiology

Matveychuk D, MacKenzie EM, Kumpula D, Song MS, Holt A, Kar S, Todd KG, Wood PL, Baker GB.
PMID: 33839994
Cell Mol Neurobiol. 2021 Apr 10; doi: 10.1007/s10571-021-01078-3. Epub 2021 Apr 10.

Phenelzine (PLZ) is a monoamine oxidase (MAO)-inhibiting antidepressant with anxiolytic properties. This multifaceted drug has a number of pharmacological and neurochemical effects in addition to inhibition of MAO, and findings on these effects have contributed to a body of...

Cite
Matveychuk D, MacKenzie EM, Kumpula D, et al. Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine. Cell Mol Neurobiol. 2021;doi: 10.1007/s10571-021-01078-3.
Matveychuk, D., MacKenzie, E. M., Kumpula, D., Song, M. S., Holt, A., Kar, S., Todd, K. G., Wood, P. L., & Baker, G. B. (2021). Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine. Cellular and molecular neurobiology, . https://doi.org/10.1007/s10571-021-01078-3
Matveychuk, Dmitriy, et al. "Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine." Cellular and molecular neurobiology vol. (2021). doi: https://doi.org/10.1007/s10571-021-01078-3
Matveychuk D, MacKenzie EM, Kumpula D, Song MS, Holt A, Kar S, Todd KG, Wood PL, Baker GB. Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine. Cell Mol Neurobiol. 2021 Apr 10; doi: 10.1007/s10571-021-01078-3. Epub 2021 Apr 10. PMID: 33839994.
Copy Download .nbib Format: NLM
Phenelzine and Amoxapine Inhibit Tyramine and d-Glucuronic Acid Catabolism in Clinically Significant .

Pathogens (Basel, Switzerland)

Burin R, Shah DH.
PMID: 33924374
Pathogens. 2021 Apr 13;10(4). doi: 10.3390/pathogens10040469.

Non-typhoidal

Cite
Burin R, Shah DH. Phenelzine and Amoxapine Inhibit Tyramine and d-Glucuronic Acid Catabolism in Clinically Significant . Pathogens. 2021;10(4)doi: 10.3390/pathogens10040469.
Burin, R., & Shah, D. H. (2021). Phenelzine and Amoxapine Inhibit Tyramine and d-Glucuronic Acid Catabolism in Clinically Significant . Pathogens (Basel, Switzerland), 10(4), . https://doi.org/10.3390/pathogens10040469
Burin, Raquel, and Shah, Devendra H. "Phenelzine and Amoxapine Inhibit Tyramine and d-Glucuronic Acid Catabolism in Clinically Significant ." Pathogens (Basel, Switzerland) vol. 10,4 (2021). doi: https://doi.org/10.3390/pathogens10040469
Burin R, Shah DH. Phenelzine and Amoxapine Inhibit Tyramine and d-Glucuronic Acid Catabolism in Clinically Significant . Pathogens. 2021 Apr 13;10(4). doi: 10.3390/pathogens10040469. PMID: 33924374; PMCID: PMC8070173.
Copy Download .nbib Format: NLM
Administration of Supplemental L-Tyrosine with Phenelzine: a Clinical Literature Review [Retraction].

Clinical pharmacology : advances and applications

[No authors listed]
PMID: 33688272
Clin Pharmacol. 2021 Mar 03;13:39. doi: 10.2147/CPAA.S308255. eCollection 2021.

[This retracts the article DOI: 10.2147/CPAA.S67271.].

Cite
Administration of Supplemental L-Tyrosine with Phenelzine: a Clinical Literature Review [Retraction]. Clin Pharmacol. 2021;13:39doi: 10.2147/CPAA.S308255.
(2021). Administration of Supplemental L-Tyrosine with Phenelzine: a Clinical Literature Review [Retraction]. Clinical pharmacology : advances and applications, 1339. https://doi.org/10.2147/CPAA.S308255
"Administration of Supplemental L-Tyrosine with Phenelzine: a Clinical Literature Review [Retraction]." Clinical pharmacology : advances and applications vol. 13 (2021): 39. doi: https://doi.org/10.2147/CPAA.S308255
Administration of Supplemental L-Tyrosine with Phenelzine: a Clinical Literature Review [Retraction]. Clin Pharmacol. 2021 Mar 03;13:39. doi: 10.2147/CPAA.S308255. eCollection 2021. PMID: 33688272; PMCID: PMC7937379.
Copy Download .nbib Format: NLM
The effect of nifedipine, Ca(2+) antagonist, on activity of MAO inhibitors, N-acetylserotonin and melatonin in the mouse tail suspension test.

The international journal of neuropsychopharmacology

Prakhie IV, Oxenkrug GF.
PMID: 11281943
Int J Neuropsychopharmacol. 1998 Jul;1(1):35-40. doi: 10.1017/S1461145798001096.

An antidepressive effect is associated with the A type monoamine oxidase (MAO) inhibitors which selectively stimulate serotonin conversion into N-acetylserotonin and melatonin. The current study compared the effect of these compounds with the non-selective MAO inhibitors and selective MAO-B...

Cite
Prakhie IV, Oxenkrug GF. The effect of nifedipine, Ca(2+) antagonist, on activity of MAO inhibitors, N-acetylserotonin and melatonin in the mouse tail suspension test. Int J Neuropsychopharmacol. 1998;1(1):35-40doi: 10.1017/S1461145798001096.
Prakhie, I. V., & Oxenkrug, G. F. (1998). The effect of nifedipine, Ca(2+) antagonist, on activity of MAO inhibitors, N-acetylserotonin and melatonin in the mouse tail suspension test. The international journal of neuropsychopharmacology, 1(1), 35-40. https://doi.org/10.1017/S1461145798001096
Prakhie, Irine V., and Oxenkrug, Gregory F.. "The effect of nifedipine, Ca(2+) antagonist, on activity of MAO inhibitors, N-acetylserotonin and melatonin in the mouse tail suspension test." The international journal of neuropsychopharmacology vol. 1,1 (1998): 35-40. doi: https://doi.org/10.1017/S1461145798001096
Prakhie IV, Oxenkrug GF. The effect of nifedipine, Ca(2+) antagonist, on activity of MAO inhibitors, N-acetylserotonin and melatonin in the mouse tail suspension test. Int J Neuropsychopharmacol. 1998 Jul;1(1):35-40. doi: 10.1017/S1461145798001096. PMID: 11281943.
Copy Download .nbib Format: NLM
Upregulation of MAOA in the hippocampus results in delayed depressive-like behaviors in burn mice.

Burns : journal of the International Society for Burn Injuries

Wang Z, Chen L, Rong X, Wang X.
PMID: 28413107
Burns. 2017 Apr 14; doi: 10.1016/j.burns.2017.03.013. Epub 2017 Apr 14.

OBJECTIVE: To observe depressive-like behavior and hippocampus monoamine oxidase A (MAOA) changes in burned mice.METHODS: We tested depression and anxiety like behaviors of burn C57 mice with the sucrose preference test, forced swimming test (FST), open field test and...

Cite
Wang Z, Chen L, Rong X, et al. Upregulation of MAOA in the hippocampus results in delayed depressive-like behaviors in burn mice. Burns. 2017;doi: 10.1016/j.burns.2017.03.013.
Wang, Z., Chen, L., Rong, X., & Wang, X. (2017). Upregulation of MAOA in the hippocampus results in delayed depressive-like behaviors in burn mice. Burns : journal of the International Society for Burn Injuries, . https://doi.org/10.1016/j.burns.2017.03.013
Wang, Zhen, et al. "Upregulation of MAOA in the hippocampus results in delayed depressive-like behaviors in burn mice." Burns : journal of the International Society for Burn Injuries vol. (2017). doi: https://doi.org/10.1016/j.burns.2017.03.013
Wang Z, Chen L, Rong X, Wang X. Upregulation of MAOA in the hippocampus results in delayed depressive-like behaviors in burn mice. Burns. 2017 Apr 14; doi: 10.1016/j.burns.2017.03.013. Epub 2017 Apr 14. PMID: 28413107.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 30 entries